Metabolic Study of Benzamidenafil using Liquid Chromatography Quadrupole Time-of-Flight Mass Spectrometry / Jaesung Pyo
Background: Various illegal phosphodiesterase-5 (PDE5) inhibitors have been indiscriminately added to food and dietary supplements since the early 2000s without evaluating their side effects or pharmaceutical effects. Objective: The metabolic pathway of benzamidenafil was evaluated using liquid chromatography quadrupole time-of-flight mass spectrometry (LC-Q-ToF-MS). Methods: In vitro metabolic samples were prepared using human liver microsomes, and in vivo metabolic samples were obtained from drug-administered rats. The metabolic samples were extracted to remove biological interferences and injected into the LC-Q-ToF-MS system for analysis. Their mass spectra and chromatograms were compared and interpreted. Results: A total of nine metabolites were evaluated in the benzamidenafil-treated samples. All error values were within 5 ppm with high accuracy. Conclusion: These newly identified metabolites of benzamidenafil could be used to construct relevant legal databases and applied to related forensic cases.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
---|---|
Enthalten in: |
Current pharmaceutical analysis - 18(2022), 6, Seite 6 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Pyo, Jaesung [VerfasserIn] |
---|
Links: |
FID Access [lizenzpflichtig] |
---|
Umfang: |
1 Online-Ressource (6 p) |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
KFL011170549 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | KFL011170549 | ||
003 | DE-627 | ||
005 | 20231128145748.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230613s2022 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)KFL011170549 | ||
035 | |a (KFL)prod_DARH_.07782093F0C34A7E2BE74EF7C09CBCF96ED98508 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
084 | |a PHARM |q DE-84 |2 fid | ||
100 | 1 | |a Pyo, Jaesung |e verfasserin |4 aut | |
245 | 1 | 0 | |a Metabolic Study of Benzamidenafil using Liquid Chromatography Quadrupole Time-of-Flight Mass Spectrometry |c Jaesung Pyo |
264 | 1 | |c 2022 | |
300 | |a 1 Online-Ressource (6 p) | ||
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Background: Various illegal phosphodiesterase-5 (PDE5) inhibitors have been indiscriminately added to food and dietary supplements since the early 2000s without evaluating their side effects or pharmaceutical effects. Objective: The metabolic pathway of benzamidenafil was evaluated using liquid chromatography quadrupole time-of-flight mass spectrometry (LC-Q-ToF-MS). Methods: In vitro metabolic samples were prepared using human liver microsomes, and in vivo metabolic samples were obtained from drug-administered rats. The metabolic samples were extracted to remove biological interferences and injected into the LC-Q-ToF-MS system for analysis. Their mass spectra and chromatograms were compared and interpreted. Results: A total of nine metabolites were evaluated in the benzamidenafil-treated samples. All error values were within 5 ppm with high accuracy. Conclusion: These newly identified metabolites of benzamidenafil could be used to construct relevant legal databases and applied to related forensic cases | ||
773 | 0 | 8 | |i Enthalten in |t Current pharmaceutical analysis |d Sharjah, U.A.E. : Bentham Science Publ., 2005 |g 18(2022), 6, Seite 6 |h Online-Ressource |w (DE-627)KFL000006440 |w (DE-600)2216923-4 |w (DE-576)306832917 |x 1875-676X |7 nnns |
773 | 1 | 8 | |g volume:18 |g year:2022 |g number:6 |g pages:6 |
856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/bentham-ejournals-pharmazie/www.eurekaselect.com/openurl/content.php?genre=article&issn=1573-4129&volume=18&issue=6&spage=608 |m X:KFL |x Verlag |y FID Access |z lizenzpflichtig |
912 | |a ZDB-1-BEJ | ||
912 | |a GBV_KFL | ||
912 | |a FID-PHARM | ||
935 | |i IMPORT_0628_prod_DARH_03 | ||
951 | |a AR | ||
952 | |d 18 |j 2022 |e 6 |h 6 |